Mankind Pharma Limited has announced the closure of its trading window for designated persons and their immediate relatives, effective January 01, 2026. This closure is in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The specific date for the Board Meeting to approve these financial results will be communicated separately in due course. This measure is a standard procedure to prevent insider trading during periods when sensitive financial information is being finalized and prepared for public disclosure.